Tuhura Biosciences Inc (HURA) Stock Price, Quote & News

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 813 875 6600

Website: www.tuhurabio.com

Address:

10500 University Center Drive, Suite 110, Tampa, United States

Royal_Imperial Apr. 25 at 10:47 PM

MITQ ✅ Has that look for next week, one of the most undervalued and cleanest micro caps. Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. A $9M projector refresh contract plus other large projects shifting into FY2026 means a significant revenue surge is likely already locked in and coming. Watching $CCTG $POET $INTC $HURA ..

0 · Reply

Emergency123 Apr. 25 at 8:31 AM

$HURA Chart looks juicy , whats a good buy in? Just picked up a load of CNBX after the laws changed. 🚀CNBX – Deep Value Biotech Flying Under the Radar 🚀 CNBX is one of those ultra-low market cap biotech plays that could move FAST when attention comes in. 💊 Cancer-Focused Pipeline CNBX is developing multiple cannabinoid-based cancer therapies, including treatments targeting colorectal, breast, prostate, and melanoma cancers. Their lead candidates like Cannabics SR and RCC-33 are aimed at massive global markets. () Got eyes on it?

0 · Reply

TuHURA_IR Apr. 24 at 1:44 PM

$HURA We have expanded our pipeline with the addition of TBS-2025 through the acquisition of Kineta, introducing a Phase 1b-ready VISTA-inhibiting monoclonal antibody. This program is designed to target acquired resistance to immunotherapy, particularly in cancers where immune suppression driven by myeloid cells limits treatment response. In AML, this represents a setting with high unmet need and limited immunotherapy options. Beyond its standalone potential, TBS-2025 also opens the door to combination strategies and future integration with our ADC platform, increasing its strategic value. As we advance toward clinical studies, this program adds another meaningful opportunity within our pipeline.

0 · Reply

Gotsomescrewsmissing Apr. 24 at 10:56 AM

$HURA

0 · Reply

JacksonHole Apr. 24 at 1:25 AM

$HURA tough hold. No idea what this trash will do day to day

0 · Reply

2TrustHim Apr. 23 at 5:55 PM

$HURA Who is buying this dip?

0 · Reply

PastaSlobCFA Apr. 23 at 3:00 PM

$HURA damn shorts

0 · Reply

michpetr Apr. 23 at 1:58 PM

$HURA cannot wait the day when you post something of value rather than this PR generated crap ....

0 · Reply

michpetr Apr. 23 at 1:57 PM

$HURA another message , actually messages and down we go.. Keep posting officials.. I jump back in at 1.8 again ;-)

0 · Reply

TuHURA_IR Apr. 23 at 1:44 PM

$HURA Thanks for highlighting this! The Special Protocol Assessment with the FDA is an important part of this, as it aligns the study endpoints and structure with what regulators expect for a potential approval pathway. In this case, overall response rate serves as the primary endpoint for accelerated approval, with progression-free survival helping support longer-term outcomes. It gives a clearer regulatory framework as the Phase 3 trial continues to enroll.

0 · Reply

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

Apr 7, 2026, 7:45 AM EDT - 18 days ago

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

Apr 1, 2026, 7:45 AM EDT - 24 days ago

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Mar 23, 2026, 7:45 AM EDT - 4 weeks ago

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Feb 27, 2026, 7:30 AM EST - 2 months ago

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 24, 2026, 5:20 PM EST - 2 months ago

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

Feb 17, 2026, 7:45 AM EST - 2 months ago

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

Feb 12, 2026, 7:45 AM EST - 2 months ago

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 2, 2026, 7:45 AM EST - 2 months ago

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

Dec 15, 2025, 7:50 AM EST - 4 months ago

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

Dec 11, 2025, 7:30 AM EST - 4 months ago

TuHURA Biosciences Provides Corporate Update Following Recent Financing

Dec 9, 2025, 9:49 AM EST - 4 months ago

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

Dec 8, 2025, 7:50 AM EST - 4 months ago

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

Nov 14, 2025, 7:00 AM EST - 5 months ago

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 3, 2025, 9:01 AM EST - 6 months ago

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

Aug 20, 2025, 8:00 AM EDT - 8 months ago

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 9 months ago

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 10, 2025, 4:00 AM EDT - 10 months ago

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Jul 1, 2025, 8:50 AM EDT - 10 months ago

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 8:50 AM EDT - 10 months ago

TuHURA Biosciences Completes Acquisition of Kineta

Jun 24, 2025, 8:00 AM EDT - 10 months ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

Jun 23, 2025, 5:00 PM EDT - 10 months ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Jun 9, 2025, 8:00 AM EDT - 11 months ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Jun 3, 2025, 9:58 AM EDT - 11 months ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Jun 2, 2025, 8:03 AM EDT - 11 months ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

May 15, 2025, 4:10 PM EDT - 1 year ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 5, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

Apr 28, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Apr 7, 2025, 8:24 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 1, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Mar 11, 2025, 8:05 AM EDT - 1 year ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 10, 2025, 9:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 20, 2024, 10:18 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

VTS

Dec 12, 2024, 8:45 AM EST - 1 year ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Nov 25, 2024, 8:35 AM EST - 1 year ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Oct 23, 2024, 8:30 AM EDT - 1 year ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 22, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 17, 2024, 4:35 PM EDT - 1 year ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Oct 16, 2024, 12:54 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Oct 16, 2024, 11:58 AM EDT - 1 year ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 9:25 AM EDT - 1 year ago

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Royal_Imperial Apr. 25 at 10:47 PM

0 · Reply

Emergency123 Apr. 25 at 8:31 AM

0 · Reply

TuHURA_IR Apr. 24 at 1:44 PM

0 · Reply

Gotsomescrewsmissing Apr. 24 at 10:56 AM

$HURA

0 · Reply

JacksonHole Apr. 24 at 1:25 AM

$HURA tough hold. No idea what this trash will do day to day

0 · Reply

2TrustHim Apr. 23 at 5:55 PM

$HURA Who is buying this dip?

0 · Reply

PastaSlobCFA Apr. 23 at 3:00 PM

$HURA damn shorts

0 · Reply

michpetr Apr. 23 at 1:58 PM

$HURA cannot wait the day when you post something of value rather than this PR generated crap ....

0 · Reply

michpetr Apr. 23 at 1:57 PM

$HURA another message , actually messages and down we go.. Keep posting officials.. I jump back in at 1.8 again ;-)

0 · Reply

TuHURA_IR Apr. 23 at 1:44 PM

0 · Reply

TuHURA_IR Apr. 23 at 1:37 PM

$HURA As we continue advancing our Phase 3 IFx-2.0 trial in Merkel Cell Carcinoma, we are doing so within a clearly defined regulatory framework under a Special Protocol Assessment with the FDA. This aligns our study design with potential accelerated approval pathways, providing clarity on how clinical success could translate into regulatory outcomes. Enrollment is ongoing, with completion expected as the study progresses toward its next stages. In parallel, we are expanding clinical activity through our Phase 1b/2a study in MCCUP, extending the reach of our lead program. If successful, this approach could expand immunotherapy access to diagnosis and patient indications where response rates remain limited today.

0 · Reply

SOFIYOLO Apr. 23 at 3:26 AM

$HURA who is the investor, kindly share name? Thanks

1 · Reply

AdityaP Apr. 22 at 10:09 PM

$HURA market always takes time to react. FYI this is same group landing them 50 M money they had over 25% ownership in company right now.. this is super bullish an private investors going all in

0 · Reply

Gamecock1 Apr. 22 at 9:33 PM

$HURA great news! Why it go down? Me so sad!

0 · Reply

AdityaP Apr. 22 at 7:51 PM

$HURA massive news.. The biggest shareholder just put $50 million of his own money in as a loan AND took a royalty on future sales. That’s the loudest possible signal of confidence you can send. He’s not just an investor anymore, he’s a lender, shareholder, AND future royalty recipient. His entire financial future is tied to this drug succeeding. $10 very much in play just this year alone

0 · Reply

DylanGFM Apr. 22 at 4:44 PM

$HURA daily support above the 200 is an extremely strong sign

0 · Reply

DylanGFM Apr. 22 at 4:30 PM

$HURA doesn't even disappoint when all the influx disperses 🤔🤔🤔📈💪🏻💰

0 · Reply

2TrustHim Apr. 22 at 3:50 PM

$HURA This Amount of Help Shows The Future Trust Of Trials And Growth!!!

0 · Reply

hhhhfdf Apr. 22 at 3:46 PM

$HURA 🟢 Bull Case Funding secured → runway to 2028 Phase 3 asset (rare for micro-cap) Analyst optimism + orphan designation Multiple catalysts in 2026–2027

0 · Reply

hhhhfdf Apr. 22 at 3:38 PM

$HURA , All remaining trial has been funded and secured. This is incredible news for compnany with ongoing Phase 3 trials.

0 · Reply

steven1x Apr. 22 at 1:10 PM

$HURA https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0001193125-26-168395/d139552d8k.htm

1 · Reply

Gantz7 Apr. 22 at 12:06 PM

$HURA 50 million credit card arrived in the Head Office post today.

0 · Reply

Market Cap	145.60M
Revenue (ttm)	0.00
Net Income (ttm)	-30.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	944,500
Avg Vol	1,199,780
Day's Range	N/A - N/A
Shares Out	63.58M
Stochastic %K	8%
Beta	-0.32
Analysts	Strong Sell
Price Target	$8.00